Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (5R00MH108719, P50MH090964, R01MH126105, R01MH036197, K99MH129611)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Brain Behavior Research Foundation
Sackler Institute for Developmental Psychobiology
American Foundation for Suicide Prevention (YIG-R-001-19)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 15 January 2022
Revised: 18 July 2022
Accepted: 21 July 2022
First Online: 1 August 2022
Competing interests
: CA has received research funding from Sunovion Pharmaceuticals, and has consulted for Ono Pharmaceuticals. None of these potential conflicts of interest are related to the subject matter discussed in this review, and they have not influenced the content of this review.